CaLiAT · A novel pathway for generation of building blocks for antibiotic biosynthesis
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-09-01 → 2018-08-31
- EU contribution
- €195,455
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
A novel pathway for generation of building blocks for antibiotic biosynthesis
Antibiotics are medicines used to prevent bacterial infections in both human and animals. Development and spread of antibiotic resistance is a universal threat to global health and food security and search for new and improved drugs is of high importance. Bacteria are a rich source of natural products with diverse chemical structures and functions; 43% of biologically active compounds originating from bacteria were isolated from bacterial species named Streptomyces. Production of the cell components (e.g. proteins, lipids, carbohydrates) that are vital for bacteria survival is named primary metabolism, whereas production of biologically active compounds (antibiotics, hormones, etc.) is named secondary metabolism. Bioengineering is a leading approach in the diversification of bacterial secondary metabolites. The aim of the project was to get the detailed understanding how Streptomyces are using a new pathway for generation of unusual building blocks that are used to assemble natural products and how scientists can use the pathway for production of new antibiotics. The key enzymes of the pathway are highly similar to those that are involved in fatty acid biosynthesis (primary metabolism) and typically are not found in secondary metabolism. The project was divided into the following parts: (a) to find additional examples of the new pathway by targeted genome sequencing and confirm the pathway identity by gene knock-outs; (b) to study the candidate enzymes from the pathway in vitro for their substrate specificity and ability to accept non-natural substrates bearing chemical functionality; (c) to generate a new derivative of a well-studied antibiotic using the newly identified pathway in vivo. Production of non-natural antibiotics will provide an attractive way both to tag antibiotics for target identification studies, and to generate novel analogues of the parent molecule as potentially valuable leads in drug discovery. This approach to extender unit alteration sufficiently contributes to the panel of tools used for targeted modification of pharmaceutically important natural products, as well as for overall competence of European science.
Data: CORDIS, © European Union
Project objective
The development and spread of antibiotic resistance in microorganisms is a major threat to both humans and animals and the search for new and improved drugs is of high importance. Natural products are experiencing a strong revival as leads in drug development, and biosynthetic engineering offers sustainable routes to new and potentially improved analogues. Finding new ways to make these rational changes should ensure that the European Research Area remains competitive in realising the potential of this technology. The aim of this project is to gain a detailed understanding of a newly-identified family of enzymes supplying unusual fatty acid building blocks for assembly-line biosynthesis of natural products; and to exploit these insights to develop more efficient strategies for targeted alteration of their structures. The novel precursor enzymes to be studied, a ligase and a biotin-dependent carboxylase, are in pathways to several polyketides produced by actinomycete bacteria.The project divides into three parts. First, additional examples of the new pathway will be sought by targetted whole-genome sequencing, as well as bio-informatic analysis of published sequence databases, and gene knockouts used to confirm the role of the pathway in providing polyketide extender units. Secondly, candidate ligases, carboxylases and the cognate acyltransferase domains that specifically recruit the unusual extender units will be studied in vitro for substrate specificity and for their ability to accept non-natural substrates bearing chemical functionality. Finally, a range of non-natural fatty acids will be fed as precursors to engineered strains designed to produce novel polyketide analogues. This approach should significantly expand the available pool of polyketide diversity. At the same time, the researcher will acquire high-level training in biochemical and chemical biology approaches that will help equip her for a leadership role in research.
Original text from CORDIS.
Participants
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGECoordinatorUnited Kingdom
Links
Data: CORDIS, © European Union
